Michael Wiederhorn
Stock Analyst at Oppenheimer
(3.70)
# 735
Out of 5,154 analysts
144
Total ratings
56.74%
Success rate
4.54%
Average return
Main Sectors:
Stocks Rated by Michael Wiederhorn
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PACS PACS Group | Maintains: Outperform | $40 → $42 | $34.28 | +22.52% | 4 | Mar 4, 2026 | |
| TDOC Teladoc Health | Maintains: Outperform | $12 → $7 | $5.08 | +37.80% | 12 | Mar 3, 2026 | |
| EVH Evolent Health | Maintains: Outperform | $12 → $6 | $3.17 | +89.27% | 2 | Mar 2, 2026 | |
| CHE Chemed | Maintains: Outperform | $580 → $500 | $407.88 | +22.59% | 14 | Feb 27, 2026 | |
| UNH UnitedHealth Group | Maintains: Outperform | $415 → $385 | $286.48 | +34.39% | 18 | Jan 28, 2026 | |
| HCA HCA Healthcare | Maintains: Outperform | $500 → $540 | $532.81 | +1.35% | 13 | Jan 28, 2026 | |
| EHAB Enhabit | Upgrades: Outperform | $14 | $13.61 | +2.87% | 3 | Jan 22, 2026 | |
| GRDN Guardian Pharmacy Services | Initiates: Outperform | $30 | $31.78 | -5.60% | 1 | Oct 10, 2025 | |
| CNC Centene | Maintains: Outperform | $51 → $43 | $43.65 | -1.49% | 19 | Jul 28, 2025 | |
| HUM Humana | Maintains: Outperform | $300 → $310 | $179.15 | +73.04% | 13 | May 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $400 → $375 | $271.63 | +38.06% | 11 | Jan 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $37 | $33.65 | +9.96% | 6 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $165 → $168 | $207.23 | -18.93% | 8 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $140 → $145 | $103.21 | +40.49% | 10 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $4.5 → $5 | $3.35 | +49.25% | 10 | Jul 25, 2024 |
PACS Group
Mar 4, 2026
Maintains: Outperform
Price Target: $40 → $42
Current: $34.28
Upside: +22.52%
Teladoc Health
Mar 3, 2026
Maintains: Outperform
Price Target: $12 → $7
Current: $5.08
Upside: +37.80%
Evolent Health
Mar 2, 2026
Maintains: Outperform
Price Target: $12 → $6
Current: $3.17
Upside: +89.27%
Chemed
Feb 27, 2026
Maintains: Outperform
Price Target: $580 → $500
Current: $407.88
Upside: +22.59%
UnitedHealth Group
Jan 28, 2026
Maintains: Outperform
Price Target: $415 → $385
Current: $286.48
Upside: +34.39%
HCA Healthcare
Jan 28, 2026
Maintains: Outperform
Price Target: $500 → $540
Current: $532.81
Upside: +1.35%
Enhabit
Jan 22, 2026
Upgrades: Outperform
Price Target: $14
Current: $13.61
Upside: +2.87%
Guardian Pharmacy Services
Oct 10, 2025
Initiates: Outperform
Price Target: $30
Current: $31.78
Upside: -5.60%
Centene
Jul 28, 2025
Maintains: Outperform
Price Target: $51 → $43
Current: $43.65
Upside: -1.49%
Humana
May 1, 2025
Maintains: Outperform
Price Target: $300 → $310
Current: $179.15
Upside: +73.04%
Jan 31, 2025
Maintains: Outperform
Price Target: $400 → $375
Current: $271.63
Upside: +38.06%
Nov 8, 2024
Maintains: Outperform
Price Target: $34 → $37
Current: $33.65
Upside: +9.96%
Oct 25, 2024
Maintains: Outperform
Price Target: $165 → $168
Current: $207.23
Upside: -18.93%
Sep 23, 2024
Maintains: Outperform
Price Target: $140 → $145
Current: $103.21
Upside: +40.49%
Jul 25, 2024
Maintains: Outperform
Price Target: $4.5 → $5
Current: $3.35
Upside: +49.25%